Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy - Concepedia

Concepedia

Publication | Closed Access

Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy

397

Citations

24

References

2003

Year

Tomás Berl, Lawrence G. Hunsicker, Julia B. Lewis, Marc A. Pfeffer, Jerome G. Porush, Jean L. Rouleau, Paul Drury, Enric Esmatjes, Donald E. Hricik, Chirag R. Parikh,

Annals of Internal Medicine

Abstract

The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.

References

	Year	Citations

Page 1